RT Journal Article
SR Electronic
T1 PET Imaging Quantifying <sup>68</sup>Ga-PSMA-11 Uptake in Metastatic Colorectal Cancer
JF Journal of Nuclear Medicine
JO J Nucl Med
FD Society of Nuclear Medicine
SP 1576
OP 1579
DO 10.2967/jnumed.119.233312
VO 61
IS 11
A1 Tahleesa J. Cuda
A1 Andrew D. Riddell
A1 Cheng Liu
A1 Vicki L. Whitehall
A1 Jennifer Borowsky
A1 David K. Wyld
A1 Matthew E. Burge
A1 Elizabeth Ahern
A1 Alison Griffin
A1 Nicholas J.R. Lyons
A1 Stephen E. Rose
A1 David A. Clark
A1 Andrew R.L. Stevenson
A1 John D. Hooper
A1 Simon Puttick
A1 Paul A. Thomas
YR 2020
UL http://jnm.snmjournals.org/content/61/11/1576.abstract
AB At diagnosis, 22% of colorectal cancer (CRC) patients have metastases, and 50% later develop metastasis. Peptide receptor radionuclide therapy (PRRT), such as 177Lu-PSMA-617, is used to treat metastatic prostate cancer. 177Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer and the neovasculature of other solid tumors, including CRC. We performed 68Ga-PSMA-11 PET/CT imaging of 10 patients with metastatic CRC to assess metastasis avidity. Eight patients had lesions lacking avidity, and 2 had solitary metastases exhibiting very low avidity. Despite expression of PSMA in CRC neovasculature, none of the patients exhibited tumor avidity sufficient to be considered for 177Lu-PSMA-617 PRRT.